Literature DB >> 17560987

Surgical management of primary lung cancer.

Robert J McKenna1.   

Abstract

Despite advancements in systemic treatment and the understanding of tumor biology, the mainstay for the treatment of lung cancer remains its resection. All patients with lung cancer should be considered surgical candidates until they are proven to have contraindications to resection. This article reviews preoperative assessment and the operative technique for the surgical treatment of lung cancer. As with other surgical specialties, thoracic surgery is moving towards minimally invasive techniques that are reducing morbidity, mortality, and length of stay. This advance is allowing patients an earlier recovery from major pulmonary surgery.

Entities:  

Mesh:

Year:  2007        PMID: 17560987     DOI: 10.1053/j.seminoncol.2007.03.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  4 in total

1.  The indication of completion lobectomy for lung adenocarcinoma ≤3 cm after wedge resection during surgical operation.

Authors:  Yiyang Wang; Rui Wang; Difan Zheng; Baohui Han; Jie Zhang; Heng Zhao; Jizhuang Luo; Jiajie Zheng; Tianxiang Chen; Qingyuan Huang; Yihua Sun; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-14       Impact factor: 4.553

2.  Is it safe to perform completion lobectomy after diagnostic wedge resection using video-assisted thoracoscopic surgery?

Authors:  Bo Laksáfoss Holbek; René Horsleben Petersen; Henrik Jessen Hansen
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-02-25

3.  Choice of the surgical approach for patients with stage I lung squamous cell carcinoma ≤3 cm.

Authors:  Chunji Chen; Yiyang Wang; Xufeng Pan; Shijie Fu; Yubo Shi; Jun Yang; Rui Wang
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

4.  Quality assessment of robot assisted thoracic surgical resection of non-small cell lung cancer: nodal upstaging and mediastinal recurrence.

Authors:  Ghada M Shahin; Besir Topal; Sjaak Pouwels; Thanasie L Markou; Rody Boon; Jos A Stigt
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.